Observing NMOSD over time for better care
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study follows people with NMOSD (a rare autoimmune disease affecting the brain and spinal cord) to learn more about the condition and how it affects patients over time. It involves regular check-ups and MRI scans, with the goal of improving future care and treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- If you have NMOSD, you need a positive AQP4-IgG blood test.
- You can also join as a healthy volunteer, matching the age and sex of the patient group.
- You should not have any other serious illnesses like cancer or severe organ problems.
- You must not be allergic to gadolinium (an MRI contrast dye).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares several medications to see which works best for NMOSD, an autoimmune disease that can cause vision loss and paralysis. You must have a specific antibody (AQP4-IgG) to join.
This trial tests a new antibody-based medicine to help people recover from an acute attack of neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation in the eyes and spinal cord. If you are having a recent flare-up and are already getting or planning to get steroid treatment, this study might offer an additional option to reduce damage and speed recovery.
This trial studies satralizumab in children ages 2 to 11 with a specific type of NMOSD caused by AQP4 antibodies. It aims to see how well the medicine prevents attacks and is safe over time.
This study uses MRI scans to look for hidden disease activity in people with NMOSD who feel stable and are already on rituximab. The goal is to catch any signs of damage early, which might help prevent future disability.
This is a registry that collects health information from adults with neuromyelitis optica spectrum disorder (NMOSD). It aims to better understand NMOSD and support future research, including studies of emerging therapies.
This trial tests a new medication called JYP0061 for people with NMOSD who are currently experiencing a sudden worsening of symptoms (acute attack). It aims to see if the drug can help control the attack and improve outcomes.
Hear when a new NMOSD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.